NCT01134510View on ClinicalTrials.gov

Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Kidney Transplantation
Interventions
DRUG

C1 Esterase Inhibitor

C1 Esterase Inhibitor 20 units/kg twice weekly x 4 weeks

DRUG

Placebos

NS (comparable volume as intervention) twice weekly x 4wks

Trial Locations (1)

90048

Cedars-Sinai medical center, Los Angeles

Sponsors

Collaborators (1)

CSL Behring
All Listed Sponsors
collaborator

CSL Behring

INDUSTRY

lead

Stanley Jordan, MD

OTHER